Bruce McClenathan, MD
Executive Medical Director, Therapeutic Lead
It’s simple, really. We have the track record and expertise to lead you through the requirements of government-funded and public health research. We collaborate with and support leading public health agencies worldwide including:
While also successfully supporting clinical trials for non-government (NGOs) and nonprofit organizations, we’re well-informed in Federal Acquisition Regulations (FAR), Defense Federal Acquisition Regulation (DFAR), Health and Human Services Acquisition Regulation (HHSAR), and International Traffic in Arms Regulations (ITAR). We identify the regulations applicable to your study or research program and support compliance.
Allucent provides flexible, global solutions that streamline clinical safety operations at the study or portfolio level in a pharmacovigilance partnership model. Leveraging the latest technology advancements in combination with deep expertise, enhances pharmacovigilance efficiency, providing high quality, complete safety oversight.
Our scientists, through their collective expertise working for big pharma, government and regulatory agencies, and academia have demonstrated proficiency in most therapeutic areas. They come well-prepared:
Allucent is built to support small and mid-sized biotechs. This approach begins and ends with the scientists we recruit and retain who have vast experience and demonstrated therapeutic expertise at all levels of clinical trial management: from our project managers to CRAs, from biostatisticians to medical writers; and regulatory affairs specialist to the principal investigator.
Allucent assists BARDA by conducting phase 1-4 clinical trials to advance research and development, manufacturing, and procurement of medical countermeasures (MCMs) that protect against health security threats such as chemical, biological, radiological, and nuclear (CBRN) incidents, pandemic influenza, COVID-19, and emerging and re-emerging infectious diseases.
Allucent has supported the following BARDA trials:
Allucent was recently selected by BARDA for its new Decentralized Clinical Operations for Healthcare and Research (D-COHRe) initiative.
Allucent supports multiple programs at the Department of Defense to advance the development of medical countermeasures (MCM) and protect soldiers from existing and emerging infectious diseases. Our support includes providing full service COVID-19 clinical trial services at various military sites in the United States, and biometric services to support the clinical evaluation of Orthopoxvirus countermeasure(s).
We support NINDS mission to advance the treatment of neurological disorders and stroke. We recently completed consulting services to support the NINDS’ HEAL Program and other NIH neuroscience-focused drug discovery and development programs to improve non-addictive therapies to treat pain.
We support NINDS mission to advance the treatment of neurological disorders and stroke. We recently completed consulting services to support the NINDS’ HEAL Program and other NIH neuroscience-focused drug discovery and development programs to improve non-addictive therapies to treat pain.
Allucent supports NIAID on multiple long-term programs which includes preclinical and clinical trial support for the development and evaluation of vaccines and therapeutic candidates. Our services include regulatory consulting for non-clinical activities and clinical trial support for Phase I-IV trials of bacterial, viral, parasitic, and fungal countermeasures to prevent and treat infectious diseases and toxins in people of all ages and risk categories.
At Allucent, we’re your trusted partner for navigating the complexities of drug development. With unparalleled expertise and a global perspective, our diverse team of US Government experts is here to guide your study to success.
Project Director Clinical Project Management
News
Learn More
News
Learn More
White Paper
Learn More
Let us know how we can help you bring new therapies to light. Get in touch to get started.
Want to help small and mid-sized biotech companies change the therapeutic landscape?